PharmGen Science팜젠사이언스
004720 · KOSPI · ₩004720 · 팜젠사이언스
- Market cap
- ₩62B
- Enterprise value
- ₩42B
- P/E
- —
- P/B
- 0.4×
- Dividend yield
- 0.0%
- ROE
- −95.9%
- Net margin
- −76.6%
Trailing 12 months from filed financial statements, as of H1 2026. Dividend yield: the 2025 dividend per share from the annual report ÷ today's price.
52-week range−38.9% from the high
₩2,590Today: ₩2,730 – ₩2,800₩4,485
Returns
- 1W−1.4%
- 1M−7.6%
- 3M−14.1%
- 6M−34.4%
- YTD−34.1%
- 1Y−34.1%
- Volume today
- 32,731
- 2.0× the 20-day average
- Traded today
- ₩91M
- Listed shares
- 22,654,365
- EPS (12 months)
- −₩5,931
- Earnings yield −216.5%
Upcoming dates
Full calendar →🎁 Gift this stock
Send a friend ₩100,000 of paper money in this stock. They get it when they join.
Signals
Normal- BuzzNormalBuzz 53: heavy trading.
- MomentumFlat-3% over the last month; the price is below its 20-day average.
- News impactLow1 news items and filings in two weeks; 0 rated high impact, 0 medium.
Signals describe activity, not recommendations. Not financial advice.
PharmGen Science stock overview
PharmGen Science (팜젠사이언스, KRX: 004720) is listed on KOSPI, in the Biotech & Pharma sector. The company operates in pharmaceuticals, healthcare (health functional foods and beauty products), and real estate leasing, leasing out its owned Palgen Science building in Bangbae-dong, Seoul. Its shares closed at ₩2,740 on Oct 28, 2026, down 0.36% on the day, giving it a market value of ₩62B.
Key facts
- Market cap
- ₩62B
- Sector
- Biotech & Pharma
- Latest price change
- −0.36%
- As of
- Oct 28, 2026
- Main business
- The company operates in pharmaceuticals, healthcare (health functional foods and beauty products), and real estate leasing, leasing out its owned Palgen Science building in Bangbae-dong, Seoul.
Quick answers about PharmGen Science
- What does PharmGen Science do?
- The company operates in pharmaceuticals, healthcare (health functional foods and beauty products), and real estate leasing, leasing out its owned Palgen Science building in Bangbae-dong, Seoul. Its pharmaceutical business centers on prescription and over-the-counter medicines, including digestive treatments, antihypertensives, lipid-lowering drugs, osteoporosis, antithrombotic and allergy medicines, and an anti-obesity treatment. Its key digestive drug, Esomax, is marketed to patients with reflux esophagitis and ulcers, and the company manufactures its medicines at its plants in Gyeonggi-do and Chungcheongbuk-do.
- What is the market cap of PharmGen Science?
- The market capitalisation of PharmGen Science was ₩62B at the close on Oct 28, 2026.
- Who are the largest shareholders of PharmGen Science?
- According to the latest official filings, the largest reported holders are Han Eui-sang (20.31%, as of May 12, 2026); Yoo Jae-man (2.52%, as of Dec 18, 2025); Han Dae-hui (2.10%, as of May 12, 2026).
- When is the next earnings report from PharmGen Science?
- Korean companies rarely announce results dates in advance. Based on when PharmGen Science filed the same report in past years, its next 3q results is expected around Nov 14, 2026.
- Does the National Pension Service own PharmGen Science?
- Yes. The National Pension Service held 0.08% of PharmGen Science shares as of Dec 31, 2025.
Company profile
The company operates in pharmaceuticals, healthcare (health functional foods and beauty products), and real estate leasing, leasing out its owned Palgen Science building in Bangbae-dong, Seoul. Its pharmaceutical business centers on prescription and over-the-counter medicines, including digestive treatments, antihypertensives, lipid-lowering drugs, osteoporosis, antithrombotic and allergy medicines, and an anti-obesity treatment. Its key digestive drug, Esomax, is marketed to patients with reflux esophagitis and ulcers, and the company manufactures its medicines at its plants in Gyeonggi-do and Chungcheongbuk-do.
Written by AI from the company's latest annual report.
- Korean name
- 팜젠사이언스
- Sector
- Biotech & Pharma
- Themes
- Biotech (new drugs)
- CEO
- 박희덕
- Founded
- Aug 1966
- Listed
- Jun 1990
- Listed shares
- 22,654,365
- Fiscal year ends
- Month 12
- Website
- www.pharmgenscience.com
Similar companies
- Samsung Biologics207940 · ₩64T₩1,372,000−0.15%
- Celltrion068270 · ₩44T₩189,800+0.64%
- Alteogen196170 · ₩16T₩223,000+2.06%
- SK biopharmaceuticals326030 · ₩5.9T₩75,200+0.40%
- Yuhan000100 · ₩5.7T₩77,300−3.38%
- HLB028300 · ₩5.4T₩40,650+1.88%
- Hanmi Pharm128940 · ₩4.7T₩369,500+5.42%
- SAM Chun Dang Pharm000250 · ₩4.5T₩190,000+1.28%
Recent filings
See all- Corporate value-up planOct 22, 2026
- Added attachment: Half-year report (Jun 2026)Aug 14, 2026
- Disclosure of Corporate Governance ReportJun 1, 2026
- Quarterly report (Mar 2026)May 15, 2026
- Amended: Annual report (Dec 2025)May 15, 2026
Titles in Korean until English translations are added.
Also known as: PharmGen Science / 팜젠사이언스 / 004720 / KRX:004720
Source: KRX statistical information